The former CAR-T cells secreting anti-PD-L1 scFv which could bind to PD-L1 on PD-L1high tumor cells and MDSCs competitively and block their binding with anti-PD-L1 monoclonal antibodies, leading to increased efficacy (165). Here, CD274 is linked to neoplasm.